featured
Gefitinib vs Cisplatin Plus Vinorelbine for Resected Stage II–IIIA EGFR-Mutated NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT)
J. Clin. Oncol 2021 Nov 02;[EPub Ahead of Print], H Tada, T Mitsudomi, T Misumi, K Sugio, M Tsuboi, I Okamoto, Y Iwamoto, N Sakakura, S Sugawara, S Atagi, T Takahashi, H Hayashi, M Okada, H Inokawa, H Yoshioka, K Takahashi, M Higashiyama, I Yoshino, K NakagawaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.